Skip to content

Net Income at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$102.3M-57.3%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$3.64M-80.8%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$19.86M+17.5%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
-$92.56M-33.6%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-$46.31M-15.8%
LBR
LB Pharmaceuticals Inc Common StockLBRX
-$19.05M-259%

Segments

By segment

See full
Reportable segment$27.14M+73.1%

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$874.19M+1,335%
Enterprise value$630.81M-940%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's net income?
Alto Neuroscience (ANRO) reported net income of -$26.24M in Q1 2026.
How has Alto Neuroscience's net income changed year-over-year?
Alto Neuroscience's net income decreased by 73.0% year-over-year, from -$15.17M to -$26.24M.
What is the long-term trend for Alto Neuroscience's net income?
Over 2 years (2023 to 2025), Alto Neuroscience's net income has grown at a 32.0% compound annual growth rate (CAGR), from -$36.31M to -$63.24M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.